Reduced irisin levels in patients with acromegaly

Suleyman Nahit Sendur; Gokhan Baykal; Busra Firlatan; Busra Aydin; Incilay Lay; Selcuk Dagdelen; Mehmet Alikasifoglu; Tomris Erbas

doi:10.1515/hmbci-2022-0009

Article

Reduced irisin levels in patients with acromegaly

Suleyman Nahit Sendur , Gokhan Baykal , Busra Firlatan , Busra Aydin , Incilay Lay , Selcuk Dagdelen , Mehmet Alikasifoglu and Tomris Erbas

Published/Copyright: July 19, 2022

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information

From the journal Hormone Molecular Biology and Clinical Investigation Volume 43 Issue 3

Abstract

Objectives

Several metabolic disturbances are seen in acromegaly however, data regarding the contribution of irisin to these disturbances is currently insufficient. In a cohort of patients with acromegaly, we measured serum irisin levels in active and controlled cases and determined independent factors that effect serum irisin including fibronectin type III domain-containing protein 5 (FNDC5) genotyping.

Methods

A cross-sectional case-control study including 46 patients with acromegaly (28 F/18 M, age: 50.3 ± 12.1 year, BMI: 30.7 ± 5.1 kg/m²) and 81 age-, gender-, body mass index- and body composition-matched healthy controls was conducted. 15 acromegalic patients (33%) had active disease. Irisin levels were measured by enzyme-linked immunosorbent assay. Three different regions (rs3480, rs1746661, and rs16835198) of FNDC5 were subjected to polymorphism analyses.

Results

Both groups were overweight and had similar body composition. Irisin levels were lower in patients with acromegaly than controls (median [IQR]: 44.8 [41.7–46.7] ng/mL vs. 51.7 [45.5–60.1] ng/mL, p≤0.001, respectively). Active and controlled patients had similar irisin levels. Irisin was not correlated with growth hormone (GH), insulin-like growth factor 1 (IGF-1), and IGF-1 index. In multiple linear regression model, somatostatin receptor ligand use (β=−20.30, 95% CI [−34]–[−6], p=0.006) was determined as the only independent factor that affect serum irisin.

Conclusions

Serum irisin levels are low in patients with acromegaly who are on somatostatin receptor ligand therapy. Single nucleotide polymorphisms (SNPs) of FNDC5 have no independent effects on circulating irisin levels under somatostatin ligand action. Endocrine muscle functions also seem to be regulated by somatostatin action, which requires further studies.

Keywords: acromegaly; FNDC5 polymorphism; irisin; somatostatin receptor ligand

Corresponding author: Suleyman Nahit Sendur, Department of Endocrinology and Metabolism, Hacettepe University School of Medicine, 06100, Sihhiye, Ankara, Turkey, Phone: +90 312 305 1148, Fax: +90 312 305 2302, E-mail: suleyman.sendur@hacettepe.edu.tr

Funding source: Hacettepe University

Award Identifier / Grant number: THD-2018-16966

Research funding: The research was supported by Hacettepe University by the project ID THD-2018-16966. The funder only had a role for material supply. The funder had no role in study design, data collection, analysis or interpretation as well as manuscript preparation and the decision to submit for publication.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: The study was approved by the institutional noninterventional clinical research ethics board (project ID: GO 17/853). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Data availability: Some or all datasets generated during and/or analysed during the current study are not publicly available but are available from the corresponding author on reasonable request.

References

1. Perakakis, N, Triantafyllou, GA, Fernández-Real, JM, Huh, JY, Park, KH, Seufert, J, et al.. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol 2017;13:324–37, https://doi.org/10.1038/nrendo.2016.221.Search in Google Scholar PubMed PubMed Central

2. Huh, JY, Dincer, F, Mesfum, E, Mantzoros, CS. Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans. Int J Obes 2014;38:1538–44, https://doi.org/10.1038/ijo.2014.42.Search in Google Scholar PubMed

3. Lee, P, Linderman, JD, Smith, S, Brychta, RJ, Wang, J, Idelson, C, et al.. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metabol 2014;19:302–9, https://doi.org/10.1016/j.cmet.2013.12.017.Search in Google Scholar PubMed PubMed Central

4. Polyzos, SA, Anastasilakis, AD, Efstathiadou, ZA, Makras, P, Perakakis, N, Kountouras, J, et al.. Irisin in metabolic diseases. Endocrine 2018;59:260–74, https://doi.org/10.1007/s12020-017-1476-1.Search in Google Scholar PubMed

5. Katznelson, L, Laws, ERJr., Melmed, S, Molitch, ME, Murad, MH, Utz, A, et al.. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3933–51, https://doi.org/10.1210/jc.2014-2700.Search in Google Scholar PubMed

6. Freda, PU, Shen, W, Heymsfield, SB, Reyes-Vidal, CM, Geer, EB, Bruce, JN, et al.. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab 2008;93:2334–43, https://doi.org/10.1210/jc.2007-2780.Search in Google Scholar PubMed PubMed Central

7. Reid, TJ, Jin, Z, Shen, W, Reyes-Vidal, CM, Fernandez, JC, Bruce, JN, et al.. IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition. Pituitary 2015;18:808–19, https://doi.org/10.1007/s11102-015-0657-2.Search in Google Scholar PubMed PubMed Central

8. Guo, X, Gao, L, Shi, X, Li, H, Wang, Q, Wang, Z, et al.. Pre- and postoperative body composition and metabolic characteristics in patients with acromegaly: a prospective study. Int J Endocrinol 2018;2018:4125013, https://doi.org/10.1155/2018/4125013.Search in Google Scholar PubMed PubMed Central

9. Reyes-Vidal, CM, Mojahed, H, Shen, W, Jin, Z, Arias-Mendoza, F, Fernandez, JC, et al.. Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J Clin Endocrinol Metab 2015;100:2946–55, https://doi.org/10.1210/jc.2015-1917.Search in Google Scholar PubMed PubMed Central

10. Kolesnikova, LI, Madaeva, IM, Semenova, NV, Osipova, EV, Darenskaya, MA. Serum myokines levels in patients with endogenous cushing syndrome and acromegaly: cross-sectional case−control study. Vestn Ross Akad Med Nauk 2016;71:240–7.10.15690/vramn659Search in Google Scholar

11. Calan, M, Demirpence, M. Increased circulating levels of irisin are associated with cardiovascular risk factors in subjects with acromegaly. Hormones 2019;18:435–42, https://doi.org/10.1007/s42000-019-00151-3.Search in Google Scholar PubMed

12. Mizera, Ł, Halupczok-Żyła, J, Kolačkov, K, Zembska, A, Grzegrzółka, J, Jędrzejuk, D, et al.. Myokines in acromegaly: an altered irisin profile. Front Endocrinol 2021;12, https://doi.org/10.3389/fendo.2021.728734.Search in Google Scholar PubMed PubMed Central

13. Melmed, S, Bronstein, MD, Chanson, P, Klibanski, A, Casanueva, FF, Wass, JAH, et al.. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 2018;14:552–61, https://doi.org/10.1038/s41574-018-0058-5.Search in Google Scholar PubMed PubMed Central

14. Giustina, A, Barkan, A, Casanueva, FF, Cavagnini, F, Frohman, L, Ho, K, et al.. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526–9, https://doi.org/10.1210/jc.85.2.526.Search in Google Scholar

15. Giustina, A, Chanson, P, Bronstein, MD, Klibanski, A, Lamberts, S, Casanueva, FF, et al.. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95:3141–8, https://doi.org/10.1210/jc.2009-2670.Search in Google Scholar PubMed

16. Li, DJ, Huang, F, Lu, WJ, Jiang, GJ, Deng, YP, Shen, FM. Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation. Acta Physiol 2015;213:711–21, https://doi.org/10.1111/apha.12421.Search in Google Scholar PubMed

17. Rachid, TL, Penna-de-Carvalho, A, Bringhenti, I, Aguila, MB, Mandarim-de-Lacerda, CA, Souza-Mello, V. Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice. Mol Cell Endocrinol 2015;402:86–94, https://doi.org/10.1016/j.mce.2014.12.027.Search in Google Scholar PubMed

18. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care 2019;42(1 Suppl):S13–28. https://doi.org/10.2337/dc19-s002.Search in Google Scholar PubMed

19. Williams, B, Mancia, G, Spiering, W, Agabiti Rosei, E, Azizi, M, Burnier, M, et al.. Practice guidelines for the management of arterial hypertension of the European society of hypertension and the European society of cardiology: ESH/ESC task force for the management of arterial hypertension. J Hypertens 2018;36:2284–309, https://doi.org/10.1097/hjh.0000000000001961.Search in Google Scholar

20. Grundy, SM, Stone, NJ, Bailey, AL, Beam, C, Birtcher, KK, Blumenthal, RS, et al.. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 2019;139:e1082–143.10.1161/CIR.0000000000000624Search in Google Scholar PubMed

21. Aleixo, GFP, Shachar, SS, Nyrop, KA, Muss, HB, Battaglini, CL, Williams, GR. Bioelectrical impedance analysis for the assessment of sarcopenia in patients with cancer: a systematic review. Oncol 2020;25:170–82, https://doi.org/10.1634/theoncologist.2019-0600.Search in Google Scholar PubMed PubMed Central

22. Abdu Allah, AM, Hammoudah, SA, Abd El Gayed, EM, El-Attar, LM, Shehab-Eldin, WA. Obesity and its association with irisin level among individuals with FNDC5/irisin gene variants RS16835198 and RS726344. Protein Pept Lett 2018;25:560–9, https://doi.org/10.2174/0929866525666180508120653.Search in Google Scholar PubMed

23. Al-Daghri, NM, Mohammed, AK, Al-Attas, OS, Amer, OE, Clerici, M, Alenad, A, et al.. SNPs in FNDC5 (irisin) are associated with obesity and modulation of glucose and lipid metabolism in Saudi subjects. Lipids Health Dis 2016;15:54, https://doi.org/10.1186/s12944-016-0224-5.Search in Google Scholar PubMed PubMed Central

24. Brondani, LA, Boelter, G, Assmann, TS, Leitão, CB, Canani, LH, Crispim, D. Irisin-encoding gene (FNDC5) variant is associated with changes in blood pressure and lipid profile in type 2 diabetic women but not in men. Metab Clin Exp 2015;64:952–7, https://doi.org/10.1016/j.metabol.2015.05.005.Search in Google Scholar PubMed

25. Khidr, EG, Ali, SS, Elshafey, MM, Fawzy, OA. Association of irisin and FNDC5 rs16835198 G>T gene polymorphism with type 2 diabetes mellitus and diabetic nephropathy. An Egyptian pilot study. Gene 2017;626:26–31, https://doi.org/10.1016/j.gene.2017.05.010.Search in Google Scholar PubMed

26. Tanisawa, K, Taniguchi, H, Sun, X, Ito, T, Cao, ZB, Sakamoto, S, et al.. Common single nucleotide polymorphisms in the FNDC5 gene are associated with glucose metabolism but do not affect serum irisin levels in Japanese men with low fitness levels. Metab Clin Exp 2014;63:574–83, https://doi.org/10.1016/j.metabol.2014.01.005.Search in Google Scholar PubMed

27. Chang, JS, Kim, TH, Nguyen, TT, Park, KS, Kim, N, Kong, ID. Circulating irisin levels as a predictive biomarker for sarcopenia: a cross-sectional community-based study. Geriatr Gerontol Int 2017;17:2266–73, https://doi.org/10.1111/ggi.13030.Search in Google Scholar PubMed

28. Huh, JY, Panagiotou, G, Mougios, V, Brinkoetter, M, Vamvini, MT, Schneider, BE, et al.. FNDC5 and irisin in humans: I. predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metab Clin Exp 2012;61:1725–38, https://doi.org/10.1016/j.metabol.2012.09.002.Search in Google Scholar PubMed PubMed Central

29. Ferraù, F, Albani, A, Ciresi, A, Giordano, C, Cannavò, S. Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol 2018;9:358, https://doi.org/10.3389/fendo.2018.00358.Search in Google Scholar PubMed PubMed Central

30. Frara, S, Maffezzoni, F, Mazziotti, G, Giustina, A. Current and emerging aspects of diabetes mellitus in acromegaly. TEM (Trends Endocrinol Metab) 2016;27:470–83, https://doi.org/10.1016/j.tem.2016.04.014.Search in Google Scholar PubMed

31. Gomes-Porras, M, Cárdenas-Salas, J, Álvarez-Escolá, C. Somatostatin analogs in clinical practice: a review. Int J Mol Sci 2020;21:1682. https://doi.org/10.3390/ijms21051682.Search in Google Scholar PubMed PubMed Central

32. Hofland, LJ, Lamberts, SW. Somatostatin receptors and disease: role of receptor subtypes. Bailliere Clin Endocrinol Metabol 1996;10:163–76, https://doi.org/10.1016/s0950-351x(96)80362-4.Search in Google Scholar

33. O’Carroll, AM, Raynor, K, Lolait, SJ, Reisine, T. Characterization of cloned human somatostatin receptor SSTR5. Mol Pharmacol 1994;46:291–8.Search in Google Scholar

34. Zhang, X, Hu, C, Yuan, YP, Ma, ZG, Tang, QZ. A brief overview about the physiology of fibronectin type III domain-containing 5. Cell Signal 2020;76:109805, https://doi.org/10.1016/j.cellsig.2020.109805.Search in Google Scholar PubMed

35. Petta, S, Valenti, L, Svegliati-Baroni, G, Ruscica, M, Pipitone, RM, Dongiovanni, P, et al.. Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2017;102:2660–9, https://doi.org/10.1210/jc.2017-00056.Search in Google Scholar PubMed

36. Metwally, M, Bayoumi, A, Romero-Gomez, M, Thabet, K, John, M, Adams, LA, et al.. A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3’UTR. J Hepatol 2019;70:494–500, https://doi.org/10.1016/j.jhep.2018.10.021.Search in Google Scholar PubMed

37. Pavlova, T, Zlamal, F, Tomandl, J, Hodicka, Z, Gulati, S, Bienertova-Vasku, J. Irisin maternal plasma and cord blood levels in mothers with spontaneous preterm and term delivery. Dis Markers 2018;2018:7628957, https://doi.org/10.1155/2018/7628957.Search in Google Scholar PubMed PubMed Central

38. Sanchis-Gomar, F, Alis, R, Lippi, G. Circulating irisin detection: does it really work? TEM (Trends Endocrinol Metab) 2015;26:335–6, https://doi.org/10.1016/j.tem.2015.05.004.Search in Google Scholar PubMed

39. Polyzos, SA, Mathew, H, Mantzoros, CS. Irisin: a true, circulating hormone. Metab Clin Exp 2015;64:1611–8, https://doi.org/10.1016/j.metabol.2015.09.001.Search in Google Scholar PubMed

Received: 2022-01-19

Accepted: 2022-06-30

Published Online: 2022-07-19

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/hmbci-2022-0009

Keywords for this article

acromegaly; FNDC5 polymorphism; irisin; somatostatin receptor ligand